Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Christgen

Showing results (101-110 of 107) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 107 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 28, 2022
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- TrialMonika Graeser, Oleg Gluz, Claudia Biehl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2023
De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP TrialNadia Harbeck, Ulrike A Nitz, Matthias Christgen, et al.
The Lancet. Oncology|May 3, 2025
Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trialSherko Kuemmel, Monika Graeser, Peter Schmid, et al.
Breast Cancer Research : BCR|February 14, 2025
HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TNGilda Schmidt, Oleg Gluz, Matthias Christgen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 3, 2022
Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancerMaxim De Schepper, Anne Vincent-Salomon, Matthias Christgen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 2, 2016
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working groupCarsten Denkert, Stephan Wienert, Audrey Poterie, et al.
The Journal of Pathology. Clinical Research|December 10, 2021
Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinomaMatthias Christgen, Leonie Donata Kandt, Wiebke Antonopoulos, et al.
Pageof 11

Showing results (101-110 of 107) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 107 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 28, 2022
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- TrialMonika Graeser, Oleg Gluz, Claudia Biehl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2023
De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP TrialNadia Harbeck, Ulrike A Nitz, Matthias Christgen, et al.
The Lancet. Oncology|May 3, 2025
Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trialSherko Kuemmel, Monika Graeser, Peter Schmid, et al.
Breast Cancer Research : BCR|February 14, 2025
HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TNGilda Schmidt, Oleg Gluz, Matthias Christgen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 3, 2022
Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancerMaxim De Schepper, Anne Vincent-Salomon, Matthias Christgen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 2, 2016
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working groupCarsten Denkert, Stephan Wienert, Audrey Poterie, et al.
The Journal of Pathology. Clinical Research|December 10, 2021
Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinomaMatthias Christgen, Leonie Donata Kandt, Wiebke Antonopoulos, et al.
Pageof 11